Mitomycin C
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | MITOMYCIN | — | 2009-08-11 | fda.gov ↗ |
| Approved | US (FDA) | MUTAMYCIN | — | 1981-08-24 | fda.gov ↗ |
Trials 165 · started per year
Also used as a comparator or background therapy in 79 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT04493073 Comparator | Dec 2020 → Dec 2021 | — | Asmaa Ahmed Ali Youssif | Unknown | No outcome recorded |
| Phase 0 | NCT03766425 Comparator | Jun 2017 → Jul 2019 | glaucoma, optic nerve disorder | Medical University of Lublin | Completed | No outcome recorded |
| Phase 0 | NCT01858025 Background | Jul 2013 → Jul 2017 | anal canal carcinoma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT05627947 Comparator | Jan 2021 → Jun 2022 | conjunctival pterygium | Egymedicalpedia | Completed | No outcome recorded |
| Phase 1 | NCT04073160 Background | Jun 2020 → Jul 2021 | urinary bladder cancer | Daniel George, MD | Withdrawn | No outcome recorded |
| Phase 1 | NCT04200417 Background | Dec 2019 → Apr 2022 | bronchial neoplasm, mediastinal cancer, pleural neoplasm, respiratory system cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03924544 Comparator | Sep 2019 → Sep 2021 | open-angle glaucoma | Cairo University | Unknown | No outcome recorded |
| Phase 1 | NCT03330028 Background | Oct 2017 → Apr 2023 | upper digestive tract disorder | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02316171 Background | Jan 2015 → Mar 2016 | non-invasive bladder urothelial carcinoma | Viralytics | Completed | No outcome recorded |
| Phase 1 | NCT01324141 Background | Mar 2011 → Apr 2015 | anal carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00999973 Comparator | Sep 2009 → ? | myopia | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1 | NCT01042782 Background | Jan 2008 → Aug 2012 | gastric cancer, gastroesophageal cancer | Krankenhaus Nordwest | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT05688488 Comparator | May 2023 → Dec 2025 overdue | congenital laryngeal web, glottis carcinoma, laryngostenosis, leukoplakia +2 | Eye & ENT Hospital of Fudan University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03844256 Background | Jan 2019 → Jul 2024 overdue | invasive carcinoma, urinary bladder cancer | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01581840 Background | Jan 2016 → Sep 2018 | anal carcinoma, squamous cell carcinoma | Federation Francophone de Cancerologie Digestive | Completed | No outcome recorded |
| Phase 1/2 | NCT02638857 Background | Sep 2015 → Mar 2017 | hepatocellular carcinoma | Second Military Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01671488 Background | Feb 2013 → Feb 2018 | anal carcinoma | Brown University | Terminated | No outcome recorded |
| Phase 219 trials | ||||||
| Phase 2 | NCT07425054 Background | Jun 2026 → Jan 2029 expected | anal squamous cell carcinoma, human papillomavirus-related squamous cell carcinoma | Jennifer Dorth | Recruiting | No outcome recorded |
| Phase 2 | NCT06770582 Comparator | Jun 2025 → Feb 2032 expected | non-invasive bladder urothelial carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT05648487 Background | Jan 2023 → Mar 2025 overdue | gastric cancer | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05200988 Background | Mar 2022 → Sep 2025 overdue | urinary bladder cancer, urothelial carcinoma | The Netherlands Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04811924 Comparator | Jul 2021 → Feb 2023 | keratoconus | Ciusss de L'Est de l'Île de Montréal | Terminated | No outcome recorded |
| Phase 2 | NCT04216290 Background | Mar 2021 → Feb 2026 overdue | urinary bladder carcinoma, urothelial carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04172675 Comparator | Feb 2020 → Jul 2024 | urinary bladder neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04230759 Background | Jan 2020 → Dec 2026 expected | anal carcinoma | Goethe University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03073694 Comparator | Jul 2017 → Jul 2024 | appendix cancer | University of Kansas Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT03018418 Background | Jan 2017 → Apr 2022 overdue | anus neoplasm | Jordan Kharofa | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02710734 Background | Feb 2016 → Nov 2025 | urothelial carcinoma | Fox Chase Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01905150 Background | Aug 2014 → Jan 2020 | malignant pancreatic neoplasm | Bruckner Oncology | Completed | No outcome recorded |
| Phase 2 | NCT03506542 Comparator | Jun 2014 → Mar 2016 | cataract, glaucoma | Medical University of Lublin | Completed | No outcome recorded |
| Phase 2 | NCT02299999 Comparator | Apr 2014 → Dec 2022 overdue | breast cancer | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01703910 Comparator | Nov 2012 | colon adenocarcinoma, metastatic neoplasm, rectum adenocarcinoma | Spanish National Cancer Research Centre | Completed | No outcome recorded |
| Phase 2 | NCT01297803 Comparator | Nov 2010 → Jun 2011 | glaucoma | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT01115517 Comparator | Oct 2010 → Jul 2015 | pterygium | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2 | NCT00949182 Background | Jul 2009 → Jun 2013 | liver cancer | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 2 | NCT00966056 Comparator | Oct 2007 → Feb 2009 | nasal cavity disorder | Karnataka Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT02901236 Comparator | Jan 2014 → Jan 2015 | glaucoma | Athens Vision Eye Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT01263834 Comparator | Dec 2010 → Jan 2014 | glaucoma | Prince of Songkla University | Completed | No outcome recorded |
| Phase 2/3 | NCT01920269 Comparator | Jan 1994 → Dec 2004 | infiltrating bladder urothelial carcinoma, non-invasive bladder urothelial carcinoma | University of Rome Tor Vergata | Completed | No outcome recorded |
| Phase 322 trials | ||||||
| Phase 3 | NCT07424287 Comparator | Jul 2026 → Jun 2030 expected | urinary bladder carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07566156 Comparator | May 2026 → Mar 2030 expected | urinary bladder neoplasm, urothelial carcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07692152 Comparator | Mar 2026 → Mar 2029 expected | anal squamous cell carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 3 | NCT06919965 Comparator | Sep 2025 → Apr 2028 expected | urinary bladder neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06319820 Comparator | Apr 2024 → Jun 2028 expected | urinary bladder carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06211764 Comparator | Apr 2024 → Nov 2030 expected | urinary bladder neoplasm | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06207981 Background | Feb 2024 → Feb 2029 expected | anal carcinoma | Federation Francophone de Cancerologie Digestive | Recruiting | No outcome recorded |
| Phase 3 | NCT05374252 Background | May 2022 → May 2025 | anal canal cancer, anal squamous cell carcinoma | Sixth Affiliated Hospital, Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT04241185 Background | May 2020 → Jan 2027 expected | urinary bladder cancer | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02982395 Comparator | Jan 2017 → Aug 2018 | urinary bladder carcinoma | Samyang Biopharmaceuticals Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT02526953 Comparator | Jan 2016 → Oct 2021 | anus neoplasm, squamous cell carcinoma | Blokhin's Russian Cancer Research Center | Unknown | No outcome recorded |
| Phase 3 | NCT02106572 Comparator | Apr 2015 → Mar 2026 | superficial urinary bladder carcinoma | Abnoba GmbH | Terminated | No outcome recorded |
| Phase 3 | NCT02369939 Background | Dec 2014 → Dec 2017 | anal carcinoma | University of Erlangen-Nürnberg Medical School | Unknown | No outcome recorded |
| Phase 3 | NCT02385370 Comparator | Dec 2014 → Dec 2015 | glaucoma | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT02301091 Background | Oct 2014 → Oct 2018 | hepatocellular carcinoma | Ming Zhao | Unknown | No outcome recorded |
| Phase 3 | NCT01489566 Comparator | Jul 2011 → Mar 2013 | hepatocellular carcinoma | Shenzhen Kangzhe Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01327521 Background | Feb 2011 → Feb 2014 | hepatocellular carcinoma | Albert Koong | Withdrawn | No outcome recorded |
| Phase 3 | NCT01200992 Comparator | Nov 2010 → Apr 2013 | in situ carcinoma, mycobacterial infectious disease, transitional cell carcinoma, urinary bladder neoplasm | Bioniche Life Sciences Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01004978 Background | Oct 2009 → Feb 2021 | hepatocellular carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00524758 Comparator | Jul 2007 → Oct 2011 | neovascular glaucoma, open-angle glaucoma, uveitis | Pro Top & Mediking Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT00296335 Comparator | Feb 2002 → Nov 2007 | gastric adenocarcinoma | Asan Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00296322 Comparator | Oct 2001 → Dec 2007 | gastric cancer | Asan Medical Center | Completed | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT07504250 Comparator | Apr 2026 → Oct 2027 expected | dacryocystitis | All India Institute of Medical Sciences, Bhubaneswar | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03875911 Comparator | Mar 2019 → Dec 2022 | open-angle glaucoma | University of California, Los Angeles | Terminated | No outcome recorded |
| Phase 4 | NCT03242317 Background | Jun 2017 → Sep 2020 | presbyopia | Fichte, Endl & Elmer Eyecare | Unknown | No outcome recorded |
| Phase 4 | NCT03101501 Background | Feb 2017 → Feb 2018 | presbyopia | Key-Whitman Eye Center | Terminated | No outcome recorded |
| Phase 4 | NCT04352660 Comparator | May 2016 → Apr 2019 | open-angle glaucoma | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT02199327 Comparator | May 2014 → Dec 2016 | conjunctival intraepithelial neoplasm, corneal intraepithelial neoplasm | Coordinación de Investigación en Salud, Mexico | Completed | No outcome recorded |
| Phase 4 | NCT02015650 Comparator | Apr 2014 → Apr 2016 | head and neck squamous cell carcinoma | Medical University Innsbruck | Terminated | No outcome recorded |
| Phase 4 | NCT01440751 Comparator | Sep 2011 → Dec 2013 | glaucoma | Aeon Astron Europe B.V. | Completed | No outcome recorded |
| Phase 4 | NCT00666237 Background | Apr 2008 → Apr 2021 | glaucoma | University of Miami | Completed | No outcome recorded |
| Phase 4 | NCT00538590 Comparator | Jul 2007 → Aug 2010 | open-angle glaucoma | Pro Top & Mediking Company Limited | Completed | No outcome recorded |
| Phase 4 | NCT00449098 Comparator | Jan 2007 → Oct 2011 | glaucoma | Pro Top & Mediking Company Limited | Unknown | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT05838391 Background | May 2023 → Dec 2026 expected | anal squamous cell carcinoma | Columbia University | Recruiting | No outcome recorded |
| — | NCT05547516 Comparator | Sep 2022 | non-invasive bladder urothelial carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| — | NCT02989207 Comparator | Aug 2016 → Dec 2017 | open-angle glaucoma | Guy's and St Thomas' NHS Foundation Trust | Unknown | No outcome recorded |
| — | NCT01174420 Comparator | Nov 2009 → Nov 2011 | open-angle glaucoma | Aeon Astron Europe B.V. | Unknown | No outcome recorded |
| — | NCT00654888 Comparator | Mar 2005 → Mar 2006 | corneal disorder | Federal University of São Paulo | Completed | No outcome recorded |
| — | NCT01504282 Comparator | — | myopia | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05494411 Background | — | renal pelvis urothelial carcinoma, ureter carcinoma | UroGen Pharma Ltd. | Available | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 255 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mitomycin C | “A Multicenter, Single-Arm Study Evaluating the Efficacy of Synergo® Radiofrequency-Induced Thermochemotherapy Effect (RITE) With Mitomycin C (Synergo® RITE + MMC) in CIS...” NCT03335059 ↗189“MitoGel is a novel investigational product composed of RTGel, a unique hydrogel polymer which exists as liquid at cold temperatures and a viscous gel at body temperatures, and...” NCT02701023 ↗ “A Randomized Multi-center Phase I/II Trial of ICM (Irinotecan, Cisplatin, Mitomycin C) With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer” NCT01296763 ↗ “This study therefore aims to evaluate the non-inferiority of HIPEC with mitomycin C 10 mg/m2 for 60 minutes versus HIEPC with mitomycin C 35 mg/m2 for 90 minutes.” NCT06513065 ↗ “A closed technique will be utilized to deliver mitomycin C (MMC) over the first 60 minutes followed by an additional smaller dose over an additional 30 minutes.” NCT05430035 ↗ “UGN-101 (Jelmyto™) is a novel formulation of mitomycin C that uses a unique hydrogel designed to increase urinary dwell time, and thereby efficacy of treatment.” PMID 32670424 ↗ Jul 2020 “0.02% mitomycin C (MMC) was applied to the bare sclera for two minutes using a soaked sponge, followed by thorough irrigation with balanced salt solution.” NCT06944132 ↗ “As part of the subjects' treatment, 10 mg/meters squared of Mitomycin C will be administered intravenously (IV-into the vein) on Day 1 and Day 29.” NCT05838391 ↗ “After enrollment, patients will be randomized into two groups: trabeculectomy with ologen (OculusGen) implant or trabeculectomy with mitomycin-C.” NCT00449098 ↗ “Comprative Study of the Safety and Effectiveness Between Oculusgen (Ologen) Collagen Matrix Implant and Mitomycin-C in Glaucoma Filtering Surgery” NCT00524758 ↗ “Efficacy of Hyaluronic Acid as Intraoperative Adjuvant in External Dacryocystorhinostomy Compared to Mitomycin-C: A Randomized Controlled Trial” NCT07504250 ↗ “Standard treatment of squamous cell carcinoma of the anus (SCCA)is 5-fluorouracil (5FU) and mitomycin C (MMC) based chemoradiotherapy (CRT).” PMID 37315583 ↗ Jun 2023 “compare concentrations of mitomycin C (MMC) in the human bladder wall after either passive delivery or electromotive administration (EMDA)” PMID 9041189 ↗ Mar 1997 “adjuvant HIPEC with Mitomycin C after colectomy in the treatment of colorectal cancer patients at high risk of peritoneal carcinomatosis.” NCT04370925 ↗ “The Mitomycin C (MMC) concentration of UGN-101 to be used in this trial will be 4 mg MMC per 1 mL of TC-3 gel, the maximum dose is 15ml.” NCT04006691 ↗ “Definitive chemoradiation with concurrent 5-fluorouracil (5-FU)/mitomycin C (MMC) is an effective treatment for localized anal cancer” PMID 31128146 ↗ May 2019 “Patients in this arm will receive a 0.2 mg/mL Mitomycin-C injection into the sclera during Ahmed Glaucoma Valve implantation surgery.” NCT06680245 ↗ “Subconjunctival injection of 0.1 ml of Mitomycin-C 0.002% at the site of future trabeculectomy surgery (2 - 4 weeks preoperatively).” NCT03875911 ↗ “Closed-abdomen HIPEC with cisplatin (25 mg/m2/l of perfusate) and mitomycin-C (3•3 mg/m2/l of perfusate) at 42•5°C for 60 minutes.” NCT02575859 ↗ “Mitomycin-C 12 mg/m², day 1 (maximum single dose 20 mg) 5-FU: 1000 mg/m² per day, continuous i.v. infusion, on day 1-4 and 29-32” NCT04230759 ↗ “5-fluorouracil (5FU) and mitomycin C (MMC)-based chemoradiotherapy (CRT) is standard treatment for anal squamous cell carcinoma.” PMID 26597443 ↗ Nov 2015 “5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal” NCT00003596 ↗ “G-FLIP-DM is low doses of Gemcitabine, Fluorouracil [5FU], Leucovorin, Irinotecan, Oxaliplatin, Docetaxel and Mitomycin C” NCT01905150 ↗ “The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU.” NCT03691441 ↗ “Mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour antibiotic activity.” NCT00386399 ↗ “subtenon injection of mitomycin C (MMC) with that of conventional application of MMC-soaked sponges” PMID 28100482 ↗ Jan 2017 “Patients who have undergone corneal cross-linking (CXL) with the application of Mitomycin C (MMC).” NCT04811924 ↗ “Comparison of Subconjunctival 5-FU Injection and Mitomycin C for Treatment of Early Bleb Failure” NCT00644215 ↗ “Mitomycin C (MMC) is known for its potent chemotherapeutic and antibiotic properties.” NCT06232005 ↗ “cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin” NCT01091168 ↗ “Capecitabine, PO, 825mg/m2 Mitomycin C, IV, 15 mg/m2 Radiotherapy - 50,4 - 54 Gy” NCT01941966 ↗ “Mitomycin C will be used as chemotherapeutic agent, for 60 min at 42-43 °C.” PMID 29439668 ↗ Feb 2018 “with mitomycin c and cisplatin will be administered following gastrectomy” NCT01683864 ↗ “concurrent mitomycin C/5-Fu chemotherapy and long-course IMRT” NCT05374252 ↗ “120 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel” NCT02307487 ↗ “Mitomycin C (MMC) and Bacillus Calmette-Guérin (BCG)” PMID 38842053 ↗ Jun 2024 “0.9％ saline solution 1L plus mitomycin C 10 mg/m2” NCT02205008 ↗ “six weekly optimized mitomycin-C instillations” NCT01675219 ↗ “intravesical mitomycin C (MMC) or gemcitabine” NCT06319820 ↗ “Mitomycin C will be used as 20mg dry powder.” NCT05024734 ↗ “all brands of Mitomycin C (MMC) are allowed” NCT04230759 ↗ “bolus IV infusion mitomycin C 6 mg/m2 day 1” NCT01530503 ↗ “Then Mitomycin C, 10mg/m2 on days 1 and 29” NCT01285778 ↗ “Mitomycin-C 20mg/m2 intravenously (day 1)” NCT00296335 ↗ “Mitomycin C 5 mg/m2 i.v. every 3 weeks” NCT01042782 ↗ “Mitomycin-C(MMC) 12 mg/m2 on day 1” NCT07425054 ↗ “specifically Mitomycin C (MMC)” NCT04352660 ↗ “Mitomycin C (10 mg/m² Day 1)” NCT04719988 ↗ “topical mitomycin-C (MMC)” NCT01523275 ↗ “mitomycin-c 12mg/m2 IV” NCT03844256 ↗ “MITOMYCIN-C 30 mg” NCT02614534 ↗ “Drug: Mitomycin c” NCT06680245 ↗ “mitomycin-C” NCT02363400 ↗ “Mitomycin C” NCT01703910 ↗ “Mitomycin C” NCT02526953 ↗ |
| Known as | JELMYTO | “This study will evaluate the efficacy and safety of UGN-104, a new formulation of UGN-101 (approved in the United States and Israel as JELMYTO \[mitomycin\] for pyelocalyceal...” NCT06774131 ↗1“UGN-101 (Jelmyto™) is a novel formulation of mitomycin C that uses a unique hydrogel designed to increase urinary dwell time, and thereby efficacy of treatment.” PMID 32670424 ↗ Jul 2020 |
| Known as | MITO | “plus Mitomycin, MITO, NSC-26980” NCT00002507 ↗ |
| Known as | Mitolem | “using intraoperative mitomycin C (Mitolem, LEMERY, S.A. de C.V. Mexico D.F. Reg. 136M92 SSA)” NCT00599950 ↗ |
| Known as | Mitomicin C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02106793 ↗ |
| Known as | mitomycin | “determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of escalating doses of Chemophase in combination with mitomycin (mitomycin C, MMC) administered...” NCT00318643 ↗70“PURPOSE: This study aimed to assess long-term follow-up after chemoresection with mitomycin (MMC), a nonsurgical treatment modality for recurrent nonmuscle invasive bladder...” PMID 36223555 ↗ Oct 2022 “standard infusion chemotherapy (including gemcitabine, mitomycin, epirubicin, etc.), dissolved in 50 mL of normal saline or glucose, and intravesical infusion chemotherapy for...” NCT05547516 ↗ “Intravesicular therapy will consist of BCG, gemcitabine, mitomycin or a similar drug, depending on institutional standards and treating provider's discretion.” NCT04073160 ↗ “UGN-104 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation.” NCT06774131 ↗ “UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation.” NCT05136898 ↗ “UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation.” NCT05243550 ↗ “UGN-103 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation.” NCT06331299 ↗ “UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation.” NCT03558503 ↗ “Patients will be treated with HIPEC using a single dose of Mitomycin 15mg/m2 and Cisplatin 50mg/m2 at 41-42 C for 90 minutes.” NCT02672865 ↗ “fluorouracil (1000 mg/m2 on days 1-4 and 29-32) plus mitomycin (10 mg/m2 on days 1 and 29) and radiotherapy (45-59 Gy)” PMID 18430910 ↗ Apr 2008 “5FU 1000 mg/m2/day as 96 hour infusion days 1-5 and 29-33; Mitomycin 10mg/m2 days 1 and 29” NCT03018418 ↗ “40 mg mitomycin with 800,000 U rHuPH20 total volume of 40 mL instilled” NCT00782587 ↗ “Chemotherapy : 5Fu (400 to 1000 mg/m²) mitomycin : 10 mg/m²” NCT01581840 ↗ “Jelmyto (gel-based mitomycin, endoluminal administration)” NCT06822010 ↗ “intraperitoneal (IP) mitomycin on day 0” NCT00005944 ↗ “Methotrexate, Mitomycin, Mitotane” NCT02788201 ↗ “plus Mitomycin, MITO, NSC-26980” NCT00002507 ↗ “Mitomycin 7mg/m2 day 5” NCT00190528 ↗ “Mitomycin 30mg/m2, d1” NCT05648487 ↗ |
| Known as | Mitomycin C (Mutamycin) | “Mitomycin C (Mutamycin)” NCT01196455 ↗ |
| Known as | Mitomycine C | “mitomycine C (day 1, 12 mg/m2, maximum dose of 20 mg)” NCT05200988 ↗ |
| Known as | MMC | “To obtain estimates of the effect on intraocular pressure and side effects of three delivery methods of Mitomycin C (MMC) compared among each other: preoperative...” NCT03875911 ↗48“Based on the observation of topoisomerase-1, upregulation by mitomycin C (MMC), and the phase I antitumor activity of sequential MMC/irinotecan in esophageal cancer, we...” PMID 20354452 ↗ May 2010 “A Multicenter, Single-Arm Study Evaluating the Efficacy of Synergo® Radiofrequency-Induced Thermochemotherapy Effect (RITE) With Mitomycin C (Synergo® RITE + MMC) in CIS...” NCT03335059 ↗ “determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of escalating doses of Chemophase in combination with mitomycin (mitomycin C, MMC) administered...” NCT00318643 ↗ “To investigate effect of intravesical mitomycin-C(MMC) applied with bladder wall thermotherapy system on reccurrence and progression status of intermediate and high risk non...” NCT03694535 ↗ “The surgical procedure includes a low dose, short duration mitomycin C (MMC) treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of...” NCT03126877 ↗ “PURPOSE: This study aimed to assess long-term follow-up after chemoresection with mitomycin (MMC), a nonsurgical treatment modality for recurrent nonmuscle invasive bladder...” PMID 36223555 ↗ Oct 2022 “Our aim was to assess if sequential mitomycin C (MMC) plus BCG after transurethral resection (TUR) is worthy of further study in non-muscle-invasive bladder cancer patients with CIS.” PMID 21156335 ↗ Dec 2010 “Although other adjuvant treatments such as steroids and antibiotics have been investigated in LTS, much attention in recent years has turned to the use of topical mitomycin-C (MMC).” NCT01523275 ↗ “The aim of this study was to define the maximum tolerated dose (MTD) of bolus mitomycin C (MMC) in combination with 24 h-continuous infusion of 5-fluorouracil (FU) plus folinic acid” NCT00289445 ↗ “A closed technique will be utilized to deliver mitomycin C (MMC) over the first 60 minutes followed by an additional smaller dose over an additional 30 minutes.” NCT05430035 ↗ “0.02% mitomycin C (MMC) was applied to the bare sclera for two minutes using a soaked sponge, followed by thorough irrigation with balanced salt solution.” NCT06944132 ↗ “Standard treatment of squamous cell carcinoma of the anus (SCCA)is 5-fluorouracil (5FU) and mitomycin C (MMC) based chemoradiotherapy (CRT).” PMID 37315583 ↗ Jun 2023 “compare concentrations of mitomycin C (MMC) in the human bladder wall after either passive delivery or electromotive administration (EMDA)” PMID 9041189 ↗ Mar 1997 “Definitive chemoradiation with concurrent 5-fluorouracil (5-FU)/mitomycin C (MMC) is an effective treatment for localized anal cancer” PMID 31128146 ↗ May 2019 “5-fluorouracil (5FU) and mitomycin C (MMC)-based chemoradiotherapy (CRT) is standard treatment for anal squamous cell carcinoma.” PMID 26597443 ↗ Nov 2015 “To compare the safety and effectiveness between ologen collagen matrix and mitomycin-C (MMC) in glaucoma surgery.” NCT00524758 ↗ “Traditionally, during trabeculectomy, Mitomycin-C (MMC) is applied to the tissues using surgical sponges.” PMID 29189540 ↗ Feb 2018 “Mitomycin-C (MMC) and Hyaluronic Acid (HA) in DCR to minimize postoperative fibrosis and ostium blockage” NCT07504250 ↗ “subtenon injection of mitomycin C (MMC) with that of conventional application of MMC-soaked sponges” PMID 28100482 ↗ Jan 2017 “one of three concentrations of Mitomycin C (MMC) (10 mg in 20 mL, 20 mg in 20 ml or 40 mg in 20 ml)” NCT02311101 ↗ “Patients who have undergone corneal cross-linking (CXL) with the application of Mitomycin C (MMC).” NCT04811924 ↗ “Among the drugs used the investigators have mitomycin C (MMC) and interferon alpha 2b (INFα 2b).” NCT02199327 ↗ “Mitomycin C (MMC) is known for its potent chemotherapeutic and antibiotic properties.” NCT06232005 ↗ “Mitomycin C (MMC) was administered at 10 mg by intravesical instillation on Day 1.” NCT02316171 ↗ “Mitomycin-C(MMC) is applied for those who not collagen matrix implanted.” NCT00538590 ↗ “doses of mitomycin C (MMC) for the treatment of pseudomyxoma peritonei.” NCT06513065 ↗ “radiotherapy and MMC (mytomicin C) and 5-FU-based chemotherapy” NCT04719988 ↗ “mitomycin (MMC) in the treatment of superficial bladder cancer” NCT00782587 ↗ “Mitomycin C (MMC) is the most used chemotherapeutic agent.” NCT03664869 ↗ “low dose, short duration Mitomycin C (MMC) during surgery” NCT03242317 ↗ “Mitomycin C (MMC) and Bacillus Calmette-Guérin (BCG)” PMID 38842053 ↗ Jun 2024 “intravesical mitomycin C (MMC) or gemcitabine” NCT06319820 ↗ “Use of Mitomycin-C (MMC) in trabeculectomy” NCT01440751 ↗ “Mitomycin-C(MMC) 12 mg/m2 on day 1” NCT07425054 ↗ “mitomycin C (MMC) and bevacizumab” NCT00294359 ↗ “Intravesical mitomycin C (MMC)” NCT05979909 ↗ “specifically Mitomycin C (MMC)” NCT04352660 ↗ “mitomycin C (MMC) 0.02%” NCT00564213 ↗ “Mitomycin C (MMC)” NCT06696794 ↗ “Mitomycin C (MMC)” NCT00974818 ↗ “mitomycin C (MMC)” PMID 19643599 ↗ Jul 2009 “Mitomycin-C (MMC)” NCT01174420 ↗ “Mitomycin C (MMC)” NCT07487168 ↗ “Mitomycin C (MMC)” NCT07646145 ↗ “Mitomycin C (MMC)” NCT04241185 ↗ “Mitomycin (MMC)” NCT02638857 ↗ “Mitomycin (MMC)” NCT07692152 ↗ “MMC” NCT04037072 ↗ |
| Known as | MMS | “The MTD of PIPAC combined with mitomycin (MMS) in the treatment of CRCPM” NCT07349043 ↗ |
| Known as | Mytomycin C | “Topical application of Mytomycin C (MMC)” NCT04037072 ↗ |
| Known as | NSC-26980 | “plus Mitomycin, MITO, NSC-26980” NCT00002507 ↗ |
| Known as | UGN-101 | “This study will evaluate the efficacy and safety of UGN-104, a new formulation of UGN-101 (approved in the United States and Israel as JELMYTO \[mitomycin\] for pyelocalyceal...” NCT06774131 ↗ |
| Known as | UGN-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04688931 ↗ |
| Known as | UGN-102 (mitomycin) for intravesical solution | “UGN-102 (mitomycin) for intravesical solution” NCT05243550 ↗2“UGN-102 (mitomycin) for intravesical solution” NCT04688931 ↗ “UGN-102 (mitomycin) for intravesical solution” NCT03558503 ↗ |
| Known as | UGN-104 (mitomycin) for pyelocalyceal solution | “UGN-104 (mitomycin) for pyelocalyceal solution” NCT06774131 ↗ |
| Action | Inhibit | “MMC has been shown to inhibit fibroblast proliferation in wound-healing processes.” NCT01523275 ↗ |
| Modality | Other / unclassified | “It is an alkylating drug that inhibits DNA from being transcribed into RNA” NCT07504250 ↗ |
| Route | Intravenous | “Patients receive IV doxorubicin, mitomycin, and cisplatin over 3 hours once every 3 weeks” NCT00002993 ↗ |